NCI-MATCH trial to begin in July

The NCI's National Clinical Trials Network (NCTN) said patient enrollment will begin in July for the Phase II NCI-MATCH trial, intended to determine whether cancer therapies can be targeted effectively to specific mutations independent of cancer type. The ECOG-ACRIN Cancer Research Group, part of NCTN, will lead the study, which it co-developed with NCI.

NCI-MATCH is designed to enroll 1,000 patients, at least 25% with rare cancers, in multiple study arms. The trial's sponsors said each arm will seek to target "actionable mutations" with a therapeutic, regardless of a patient's cancer type. ...